<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00142038</url>
  </required_header>
  <id_info>
    <org_study_id>AGST-Magen-CapDoc-04</org_study_id>
    <nct_id>NCT00142038</nct_id>
  </id_info>
  <brief_title>Docetaxel and Capecitabine in Advanced Gastric Cancer</brief_title>
  <official_title>Phase II Study of Docetaxel and Capecitabine as 1st Line Therapy for Patients With Locally Advanced or Metastatic Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <brief_summary>
    <textblock>
      Up to date there is no worldwide accepted standard chemotherapy for the 1st-line treatment of&#xD;
      advanced or metastatic gastric cancer.A combination of epirubicin, cisplatin and 5-FU (ECF)&#xD;
      is the best examined combination and widely used. Recent studies (Thuss-Patience et al, J.&#xD;
      Clin. Oncol. 2005) could show that a combination of docetaxel and 5-FU might be similarly&#xD;
      effective as ECF. 5-FU and docetaxel +/- cisplatin combinations are investigated by many&#xD;
      groups and may be a future reference treatment. Many data suggest that 5-FU infusion can be&#xD;
      replaced by oral capecitabine with equal efficacy.&#xD;
&#xD;
      As docetaxel/5-FU is probably similarly effective as epirubicin/cisplatin/5-FU and a&#xD;
      replacement of 5-FU infusion by capecitabine makes the chemotherapy more comfortable for the&#xD;
      patient we investigate in this study a chemotherapy of docetaxel and capecitabine as 1st-line&#xD;
      therapy for metastatic or advanced gastric cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with locally advanced or metastatic gastric adenocarcinoma who did not receive any&#xD;
      prior chemotherapy for advanced disease can be enrolled in the study.&#xD;
&#xD;
      Patients are treated with oral capecitabine 1000mg/sqm twice per day on the days 1-14 and&#xD;
      docetaxel 75 mg/sqm on day 1 as a 1 hour i.v. infusion. chemotherapy is repeated every 21&#xD;
      days. Staging by imaging is performed every 2 cycles.&#xD;
&#xD;
      After 40 included patients an amendment was done and the starting of chemotherapy has been&#xD;
      reduced to further improve tolerability. Starting dose of docetaxel was amended to 60 mg/sqm,&#xD;
      d1, and starting dose of capecitabine reduced to 800 mg/sqm twice per day, d1-14. The patient&#xD;
      number to be included was increased to 70 pts.&#xD;
&#xD;
      Therapy is continued up to tumor progression to a maximum of 10 cycles. Therapy is stopped in&#xD;
      case of severe side effects, tumor progression or withdrawal of consent.&#xD;
&#xD;
      This investigator initiated study is supported by Hoffmann-La Roche and by Sanofi-Aventis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date>December 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
  </secondary_outcome>
  <enrollment>80</enrollment>
  <condition>Stomach Neoplasm</condition>
  <condition>Neoplasm Metastasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically proven adenocarcinoma of the stomach or the GE-junction.&#xD;
&#xD;
          -  Patients with distant metastases or patients with locally advanced disease who are not&#xD;
             curatively operable proven by laparoscopy or patients with a recurrence after&#xD;
             gastrectomy.&#xD;
&#xD;
          -  Patients who did not receive any prior palliative chemotherapy. An adjuvant&#xD;
             chemotherapy is allowed.&#xD;
&#xD;
          -  Age between 18 and 75 years.&#xD;
&#xD;
          -  Sufficient bone marrow function defined as leucocytes &gt; 3.0 Gpt/l, thrombocytes &gt; 100&#xD;
             Gpt/l&#xD;
&#xD;
          -  Sufficient liver function defined as bilirubin &lt; 1.5 mg/dl (1.5 x ULN), ALT and AST &lt;&#xD;
             3 x ULN.&#xD;
&#xD;
          -  Sufficient renal function defined as serum creatinine &lt; 1.25 x ULN, or creatinine&#xD;
             clearance &gt; 60 ml/min calculated according to Cockroft-Gault&#xD;
&#xD;
          -  Contraception in patients with reproductive potential.&#xD;
&#xD;
          -  Karnofsky-performance-index at least 60%&#xD;
&#xD;
          -  Measurable tumor lesions.&#xD;
&#xD;
          -  Written informed consent of the patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Karnofsky-performance-index less or equal 50%.&#xD;
&#xD;
          -  Patients who already received a palliative first-line chemotherapy.&#xD;
&#xD;
          -  Prior second malignancy, except basal cell carcinoma of the skin or curatively treated&#xD;
             carcinoma in situ of the cervix.&#xD;
&#xD;
          -  Parallel radiation therapy&#xD;
&#xD;
          -  Uncontrolled infection.&#xD;
&#xD;
          -  CNS-metastasis&#xD;
&#xD;
          -  Other severe medical disease&#xD;
&#xD;
          -  Prior major surgery for less than 2 weeks&#xD;
&#xD;
          -  Parallel treatment with other experimental therapies.&#xD;
&#xD;
          -  Parallel treatment with any other therapy aiming against the tumor.&#xD;
&#xD;
          -  Chronic diarrhea, subileus.&#xD;
&#xD;
          -  Chronic inflammatory bowel disease or intestinal obstruction.&#xD;
&#xD;
          -  Unable to take oral medication.&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>P Reichardt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité, University, Campus-Virchow-Klinikum, Dept. of Hematology and Oncology, Berlin,</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P C Thuss-Patience, MD, PhD, Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité, University, Campus Virchow-Klinikum, Dept. of Hematology and Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité, Universitätsmedizin Berlin, Campus Virchow-Klinikum, Dept. of Hematology and Oncology</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.charite.de</url>
    <description>Charité University Clinic, Berlin</description>
  </link>
  <reference>
    <citation>Thuss-Patience PC, Kretzschmar A, Repp M, Kingreen D, Hennesser D, Micheel S, Pink D, Scholz C, Dörken B, Reichardt P. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol. 2005 Jan 20;23(3):494-501.</citation>
    <PMID>15659494</PMID>
  </reference>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>September 1, 2005</study_first_submitted>
  <study_first_submitted_qc>September 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2005</study_first_posted>
  <last_update_submitted>April 17, 2007</last_update_submitted>
  <last_update_submitted_qc>April 17, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2007</last_update_posted>
  <keyword>gastric cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>locally advanced</keyword>
  <keyword>docetaxel</keyword>
  <keyword>capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

